Announcements Trials
Browse Landscape

Status

Completed 2Unknown 1

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 103Observational 3Expanded_access 1

Sponsor

Cancer Type

Breast 3Genitourinary 1

Conditions

Carcinoma, Renal Cell 3Breast Neoplasms 3Neuroendocrine Tumors 2Neoplastic Cells, Circulating 1Lymphangioleiomyomatosis 1Carcinoma, Hepatocellular 1Adenoma, Islet Cell 1

Interventions

Surveys and Questionnaires 70Blood Specimen Collection 60palbociclib 37Trastuzumab 31Letrozole 26Immunohistochemistry 26Drug Therapy 24Anastrozole 24Radiotherapy 21Gene Expression Profiling 20Amplified Fragment Length Polymorphism Analysis 20Mastectomy, Segmental 19Biopsy 19Tamoxifen 18exemestane 17Interviews as Topic 17ribociclib 16Mastectomy 16Fulvestrant 16Paclitaxel 15Magnetic Resonance Spectroscopy 15Psychiatric Rehabilitation 14High-Energy Shock Waves 14Polymerase Chain Reaction 13Observation 13Microarray Analysis 13Capecitabine 13trastuzumab deruxtecan 12Neoadjuvant Therapy 12Specimen Handling 11

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Observational × Breast Neoplasms × Everolimus × Clear all
NCT04212702 2021-01-12

ESR1 Mutations in Asian ER+ Metastatic Breast Cancer on Hormonal Therapy-based Treatments

National Taiwan University Hospital

Unknown
123 enrolled
Breast

Breast Neoplasms

NCT02809404 2017-10-16

SPOT

Radboud University Medical Center

Completed
75 enrolled
BreastGenitourinary

Breast Neoplasms, Carcinoma, Renal Cell

NCT02023359 2015-12-29

Danish Observational Study of Everolimus Plus Exemestane in Hormone Receptor (HR) Positive, Human Epidermal Growth Factor 2 (HER2) - Metastatic Breast Cancer

Novartis

Completed
7 enrolled
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡